Climate Change Data

Mochida Pharmaceutical Group (Mochida Pharmaceutical Co., Ltd. and its consolidated subsidiaries)

Climate Impact & Sustainability Data (2023-04 to 2024-03)

Reporting Period: 2023-04 to 2024-03

Environmental Metrics

Total Carbon Emissions:15,142 t-CO2e/year (FY2023)
Scope 1 Emissions:4,313 t-CO2e/year (FY2023)
Scope 2 Emissions:10,431 t-CO2e/year (FY2023)
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:347 TJ/year (FY2023)
Water Consumption:306,000 m3/year (FY2023)
Waste Generated:533 tons/year (FY2023)
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Human resource development
  • Compliance
  • Creation of unique products to meet needs
  • Stable supply of high-quality pharmaceuticals
  • Proper provision of valuable information
  • Climate change
  • Human rights
  • Women's health

Environmental Achievements

  • Reduced CO2 emissions by 15.4% from FY2013 levels by FY2023
  • Headquarters building received a top-level BELS 5-star rating and was certified as “ZEB Ready”
  • Replaced below-ground drainage system with an above-ground system at Head Office Plant to prevent soil contamination

Social Achievements

  • Launched project to raise awareness about ulcerative colitis
  • Introduced integrated service for resolving women’s health issues
  • Received the Minister of Health, Labour and Welfare’s “Kurumin” certification

Governance Achievements

  • Established the Nomination and Compensation Advisory Committee
  • Established the Ethics and Compliance Committee
  • Established the Risk Management Committee

Climate Goals & Targets

Long-term Goals:
  • Reach carbon neutrality by 2050
  • Total net sales of 140 billion yen and an operating margin of 15% by 2031
Medium-term Goals:
  • Reduce carbon emissions by 46% from FY2013 levels by FY2030
  • Reduce waste to 582 tons or lower by FY2030
  • Increase waste recycling rate to 98% or higher by FY2030
  • Maintain a plastic waste recycling rate of 65% or higher by FY2030
  • Target ratio of female managers of 12% or higher (FY2021-FY2025)
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Challenging market conditions for ethical drugs in Japan (governmental promotion of generic drug usage and new drug patent cliff)
  • Decreased sales due to annual NHI drug price revisions
  • Instability of pharmaceuticals supply
  • Rising prices due to a weaker yen
  • Increasing complexity of new drug development
  • Increasingly diverse drug discovery modalities
  • Competition with rival products (including generics)
  • Climate change risks (physical and transition risks)
Mitigation Strategies
  • Concentration of total power of the Group covering research and development, manufacturing and marketing
  • Selection and focusing processes
  • Restructuring the earnings structure
  • Active rollout of energy conservation measures
  • Upgrading to high-efficiency, energy-saving equipment
  • Adoption of renewable energy
  • Formulate specific action guidelines (BCP) for disasters
  • Ensuring Diversified Procurement Sources
  • Appropriate inventory control
  • Implementation of assessments of stability of water supply and drought at existing sites

Supply Chain Management

Supplier Audits: Over 80% response rate to sustainability survey of business partners (FY2023)

Responsible Procurement
  • Sustainable Procurement Policy
  • Sustainable Procurement Guidelines

Climate-Related Risks & Opportunities

Physical Risks
  • Increase in severity and frequency of weather-related disasters
  • Temperature rise
  • Water shortages
Transition Risks
  • Tightening of decarbonization-related policies, laws and regulations
  • Increased burden of carbon taxes
Opportunities
  • Enhancing corporate value through climate change initiatives
  • Growing demand for pharmaceuticals to treat specific diseases associated with rising temperatures

Reporting Standards

Frameworks Used: International Integrated Reporting Framework

Certifications: ISO 14001

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Epadel EM (self-emulsifying formulation)
  • Treprost Inhalation Solution
  • Omvoh and Cortiment (ulcerative colitis treatments)
  • Collage Furfur series (antimycotic ingredients)
  • Collage Repair series (basic skin care products)
  • dMD-001 (articular cartilage lesion restoration material)
  • ReFeel® (nerve regeneration material)

Awards & Recognition

  • Not disclosed